Vesalius
Vesalius connects providers and pharmacies. The licensed prescriber and the participating pharmacy fit together like two pieces of one puzzle, and Vesalius keeps the quality documentation that joins them.
Peptide PrescriptionsThrough Participating Pharmacies
Vesalius connects licensed prescribers with participating pharmacies for patient-specific peptide prescriptions.
Mission
Vesalius closes the gap between longevity science and clinical practice in one platform.
Manufactured in the
United States
Vesalius peptides are dispensed through participating pharmacies.
From the Manufacturer to the Pharmacy
There are steps between a bulk manufacturer and a patient receiving medication, and each one leaves a record. Turn the wheel to follow a lot from where it is made, through testing and documentation, to the participating pharmacy that dispenses it.
01Origin
Sourcing
Contact our provider team for product-specific sourcing and manufacturing information.
02Testing
Identity and Purity
Substance identity and purity certified.
03Records
Certificate of Analysis
Each lot’s test results are recorded in a certificate of analysis. A certificate documents the results of testing for a specific lot.
04Access
Dispensed by Participating 503A Pharmacies
Patient-specific prescription from a licensed prescriber required.
Product and Pharmacy Information
Contact Vesalius with questions about current products and participating pharmacies.
Information for New Providers
Ask about provider eligibility, participating pharmacies, current products and the process for submitting a prescription.
Request Provider Information
Account Inquiries
Contact Vesalius about your account, current product availability or the process.
Ask About Your AccountOur Physicians, Scientists, and Operators
Latest Announcements
-
November 12, 2026Read the Release
Vesalius Longevity Labs Commences Trading Today on the Canadian Securities Exchange Under the Symbol “VLAB”
Vesalius Longevity Labs Inc. (CSE: VLAB) commenced trading on the Canadian Securities Exchange under the symbol “VLAB” today, November 12, 2026.
-
November 10, 2026Read the Release
Vesalius Longevity Labs Announces Commencement of Trading on the Canadian Securities Exchange Under the Symbol “VLAB”
Vesalius Longevity Labs Inc. (CSE: SE) (to trade as “VLAB”) will commence trading on the Canadian Securities Exchange under the symbol “VLAB” on November 12, 2026, further to its Listing Statement dated November 9, 2026.
-
November 9, 2026Read the Release
Vesalius Longevity Labs Closes Strategic Financing of US$6.5 Million, Led by Investor Group Organized by Harvey Spevak
Vesalius Longevity Labs Inc. (CSE: SE, to trade as “VLAB”) has completed a non-brokered private placement of 6,190,475 units at US$1.05 per Unit, for aggregate gross proceeds of US$6,499,998.75, led by an investor group organized by Harvey Spevak, Chairman of Equinox Group.
-
October 29, 2026Read the Release
Celularity and Vesalius Longevity Labs Sign Exclusive Collaboration for Peptual® Peptide APIs Manufactured in the United States
Celularity will serve as the exclusive partner for the finish manufacturing of Vesalius’s Peptual peptide APIs, establishing a United States final-stage API manufacturing and supply platform.
-
October 29, 2026Read the Release
Vesalius Announces Closing of Reverse Takeover Transaction
Vesalius Longevity Labs Inc. has closed its previously announced business combination with Vesalius Longevity Labs (Canada) Inc. and Vesalius Longevity Labs (SPV) Inc.